---
run_id: halo-evidence-vs-diagnosis-validation-v9-vanilla-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
model_condition: vanilla
run_number: 6
model_name: gemma-4-31b-it-mlx
model_id: gemma-4-31b-it-mlx
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
max_tokens: 1024
seed: 601
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
condition_packet_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
output_file: model-outputs/vanilla-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v9-v1`, condition `vanilla`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx` via lmstudio, seed 601, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### The Recommendation: Claim File Review
The company is currently experiencing a "false positive" signal. Your revenue growth is driven by temporary pricing incentives and sales narratives, not product value. Meanwhile, your usage data is skewed by managers performing "audit" behavior rather than adjusters performing "workflow" behavior.

The Claim File Review is the only option that penetrates this noise to find the **ground truth of utility**. By inspecting the actual claim files, you can determine if DraftPath is solving a problem or simply creating "administrative theater" where adjusters use the tool to satisfy managers but rewrite the output to actually do their jobs. This allows you to determine if the product needs a pivot (e.g., adding "explainability" for regulated health) or if the value proposition is fundamentally flawed before you lock in a budget based on phantom growth.

### The Strongest Reason Against It
**It is slow and qualitative.** Unlike the Usage Quality Sprint or the Commercial Cleanroom, this method does not provide a statistically significant "number" to show the board. It is labor-intensive and relies on small sample sizes, which may make it difficult to justify to a CEO who is currently riding a wave of 16% expansion growth and wants to "scale" the success.

### The Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "regional carrier" churn (the two accounts removing DraftPath) was driven primarily by a lack of budget/procurement issues rather than product dissatisfaction. If the product is fundamentally loved but the pricing model is broken, you don't need a file review—you need to test price elasticity and buyer intent.
